"Side effects of Vero cell vaccination against Covid-19 among medical students of Nepalgunj Medical College"-A Post Vaccination survey

Rupak KC¹, Sibika Malla¹, Merina Shrestha¹, Aashish Jung Pandey¹, Saharoj Siddiqui¹, Suraj Adhikari², Niranjan KC³, Rumi KC⁴

1.Nepalgunj Medical College, Banke, Nepal

2. Matrishishu Miteri Government Hospital, Gandaki, Nepal

3.Patan Academy of Health Sciences, Lalitpur, Nepal

4.Sahid Gangalal National Heart Center, Kathmandu, Nepal

Abstract

Background

Severe Acute Respiratory Syndrome Corona Virus 2 (SARS-CoV-2) is a highly transmissible virus causing Coronavirus disease (COVID-19). Its key symptoms include fever, dry cough, and shortness of breath. Vaccine plays a significant role in controlling infectious disease, and reduction of the use of health service leaving more resources for the treatment of other diseases.2 Vero Cell is an inactivated vaccine against COVID-19 manufactured by Sinopharm Company of China and recommended for people above 18 years by the World Health Organization. It is administered in two doses of 0.5 ml, 14-28 days apart.

Methods and findings

A prospective cross-sectional study was conducted among undergraduate medical students and intern doctors of Nepalgunj Medical College after receiving ethical approval from the institutional review committee of this college. Demographic features of the study population and the frequency and percentages of side effects among the population who received the vaccines were calculated along with the duration of symptoms. All undergraduate medical students and intern doctors of Nepalgunj Medical College who received two doses of the Vero Cell vaccine against COVID-19 were involved in the study. Those who failed to give written consent and those who were not willing to receive both doses of vaccine were excluded. Data were collected using a self-administered structured questionnaire. The eligible participants were provided with the questionnaire twice, after administration of each dose of vaccine. Collected data were entered in structured Pro-forma and analyzed statistically in Microsoft Excel 2019 MSO (Version 2021). About 75% of the participants had one or more symptoms after the first dose of the vaccine, which reduced to 62% after the second dose. Symptoms were more in males after the first dose (76% vs. 72%), but the reverse was seen after the second dose (54% vs. 77%). Pain NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

at the injection site was the most commonly reported side effect (27%) followed by myalgia (20%). No individuals receiving both doses of vaccine had diarrhea, difficulty in breathing, tingling sensation, or anaphylactic reaction. A higher percentage of females experienced pain at the injection site after the second dose over the first than males. However, males experienced fatigue more than females after every dose. Pain at the injection site and Myalgia were common symptoms to start early, within 12 hours post-vaccination. However, fatigue was seen maximally 24 hrs post-vaccination. Fever was seen in 7% of participants within 12 hours of vaccination. Cough and sore throat as side effects persisted up to 2 weeks after vaccination. The main limitation of the study is the low sample size.

Conclusions

Pain at the injection site was the most common AEFI followed by Myalgia with other insignificant effects. There were no life-threatening side effects. A larger study on the general population including all age groups is highly recommended to detect all spectrum of side effects.

INTRODUCTION

The virus that is the root cause of the highly threatening global pandemic has been designated as severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing the coronavirus disease (COVID-19).¹ As per the reports, this virus was first discovered in persons exposed to a seafood wholesale wet market in Wuhan, China.² By the 31st of December, the Wuhan Municipal Health Commission had given out its alert.³ Soon this disease enveloped the entire world and was announced as a pandemic by the World Health Organization on the 11th of March, 2020.⁴ Till February 3, 2022, a total of 385,967,643 cases of COVID-19 has been confirmed out of which 5,721,171 has died and 305,840,220 has been recovered.⁵

SARS-CoV-2 is the third coronavirus after SARS-CoV(2002) and MERS-CoV(2012) which has a high case fatality rate of 4.8%.^{6,7} It is a single-stranded, spherical, or pleomorphic enveloped RNA virus whose club-shaped protrusions cover them like a crown and this is also the reason for its naming.^{8,9} The SARS-CoV-2 can be transmitted through direct contact, air, fomite, or fecal-oral route. Similarly, blood-borne, mother to child, or animal to human transmission of this virus has also been found.¹⁰ Its key symptoms include fever, dry cough, and shortness of breath. Pneumonia is its major complication.¹¹ The first positive case of COVID-19 in Nepal was confirmed in a girl who returned from Wuhan Institute of Technology, Wuhan, China on the 13th of January, 2020.¹² As of 12 February 2021, the total confirmed cases here was 972,632 out of which 11,882 had died.⁵ The only hope in this dark phase is the vaccine that can end the pandemic. Safe and effective vaccines are a game-changing tool. Vaccine plays a significant role in controlling infectious disease, reduction of the use of health services because of infectious diseases, and leaving more resources for the prevention and treatment of other diseases.¹³ It prevents people from being infected or getting gravely sick. It averts the person from spreading

COVID-19 to others and thus making it difficult for the disease to escalate, contributing to herd immunity.^{14,15} Till 2 February 2022, 33 vaccines have been approved for clinical use and 65 vaccines are in their phase three trials.¹⁶ The vaccination program has begun in Nepal on 27th January 2021 after India provided one million doses of the Covid-19 covishield vaccine, developed by the University of Oxford and pharmaceutical giant AstraZeneca and locally produced by the Serum Institute of India, the world's largest vaccine company.¹⁷ At the beginning of March, COVAX, an international vaccinesharing scheme supported by the United Nations, supplied 348,000 doses of Covishield. Beijing delivered 800,000 doses of Vero Cell under grant assistance at the end of March. Again, in June, an additional 1 million doses of Vero Cell under a Chinese grant then arrived Nepal.¹⁸

Vero Cell is an inactivated vaccine manufactured by Sinopharm Company of China which is recommended safe to be used for people above 18 years by the World Health Organization. It is administered in two doses of 0.5 ml each. The second dose is administered 14-28 days after the first one.¹⁹ According to the estimation of the global health agency, the overall efficacy of Vero cell is about 78%.²⁰ Many people who have been vaccinated are experiencing side effects in one form or the other. Outside of clinical trials situation, only a few data are available which has assessed its safety. This research aims to assess the post-vaccination side effects of Vero Cell in the undergraduate medical students and medical interns of Nepalgunj medical college.

MATERIALS AND METHODS

Study design

A prospective cross-sectional study was conducted among undergraduate medical students and intern doctors of Nepalgunj Medical College after receiving ethical approval from the institutional review committee of this college.

Sample size and sampling techniques:

The total number of participants in this survey was 122.

Inclusion and Exclusion Criteria: All undergraduate medical students and intern doctors of Nepalgunj Medical College who received two doses of the Vero Cell vaccine against COVID-19 were involved in the study. Those who failed to give written consent and those who were not willing to receive both doses of vaccine were excluded.

Statistical Analysis:

Data were collected using a self-administered structured questionnaire. The eligible participants were provided with the questionnaire twice, after administration of each dose of vaccine. Collected data were entered in structured Pro-forma and analyzed statistically in Microsoft Excel 2019 MSO (Version 2021)

RESULTS

Out of the total participants, the majority (68%) were males with a Male: Female ratio of 17:8. Most of the participants were intern doctors (38%) and 85% of participants belonged to the age group of 20-25 years.

SN	Parameter	No. (%)
1.	Gender	Male 83 (68%)
		Female 39 (32%)
2.	Year of Study	First 6 (5%)
		Second 6 (5%)
		Third 32 (26%)
		Final 32 (26%)
		Intern 46 (38%)
3.	Age	18-20 years 1 (0.8%)
		20-25 Years 107 (85%)
		>25 Years 17 (14%)

Table 1:	Demographic	parameters
----------	-------------	------------

About 75% of the participants had one or more symptoms after the first dose of the vaccine, which reduced to 62% after the second dose. Symptoms were more in males after the first dose (76% vs. 72%), but the reverse was seen after the second dose (54% vs. 77%).

Dose	Symptoms	Male (%)	Female (%)	Total (%)	
1 st Dose	Seen	63 (75.9)	28 (71.8)	91 (74.6)	
	Not Seen	20 (24.1)	11 (28.2)	31 (25.4)	
2 nd Dose	Seen	45 (54.2)	30 (76.9)	75 (61.5)	
	Not Seen	38 (45.8)	9 (23.1)	47 (38.5)	

Pain at the injection site was the most commonly reported side effect (27%) followed by myalgia (20%). No individuals receiving both doses of vaccine had diarrhea, difficulty in breathing, tingling sensation, or anaphylactic reaction. A higher percentage of females experienced pain at the injection site after the second dose over the first than males. However, males experienced fatigue more than females after every dose.

Table 3: Frequency of symptoms:

SN	Symptoms	Count (Percentage)*
1.	Most Common	219 (63.1%)
	Pain at the site of Injection (26.5%), Myalgia (20.2%), Fatigue (16.4%)	
2.	Less Common	128 (36.9%)
	Swelling (0.3%), Redness (1.4%) Itching (7.5%), Fever	
	(7.8%), Joint Pain (2.9%), Fatigue (16.4%), Cough (1.4%), Sneezing (0.9%), Sore Throat (1.7%), Runny Nose (0.3%),	
	Nausea and Vomiting (0.9%) , Headache (5.2%) , Dizziness $(2,7\%)$ Shire Bacher $(2,0\%)$	
	(3.7%), SKIN Kasnes (2.9%)	

*Count more than total participants due to multiple symptoms in each individual

Pain at the injection site and Myalgia were common symptoms to start early, within 12 hours postvaccination. However, fatigue was seen maximally 24 hrs post-vaccination. Fever was seen in 7% of participants within 12 hours of vaccination. Cough and sore throat as side effects persisted up to 2 weeks after vaccination.

Table 4: Duration of symptoms

SN	Duration of Symptoms	A	В	С	D	E	F	G
1.	Swelling	0.4%	0.4%	-	-	-	-	-
2.	Redness	1.8%	0.9%	-	-	-	-	-
3.	Itching	6.4%	4.8%	6.0%	-	-	-	-
4.	Fever	7.1%	7.0%	4.0%	-	-	-	-
5.	Pain at the site of Injection	25.4%	24.5%	34.0%	7.1%	-	-	-
6.	Muscle Pain	20.8%	22.7%	16.0%	7.1%	16.7%	-	-
7.	Joint Pain	8.8%	2.6%	2.0%	7.1%	16.7%	-	-
8.	Fatigue	16.6%	24.0%	30.0%	50.0%	16.7%	-	-
9.	Cough	0.7%	-	-	7.1%	16.7%	50.0%	-
10.	Sneezing	-	0.4%	-	7.1%	16.7%	-	-
11.	Sore Throat	1.1%	0.9%	1.0%	-	-	50.0%	-
12.	Headache	4.6%	3.5%	1.0%	7.2%	16.5%	-	-
13.	Dizziness	3.5%	3.5%	-	-	-	-	-
14.	Skin Rashes	2.8%	3.9%	5.0%	7.3%	-	-	-

A = Less than 12 hours; B = 12-24 hours; C = 24-48 hours; D = 48-72 hours E = PostVaccination Day (4th day to 7th Day) F = After 1-2 weeks; G = 2 weeks and above.

Discussion:

Out of 122 medical students included in the study, Pain at the injection site was the most common presentation accounting for about 26.5% whereas, in the study conducted by Osama Abu-Hammad et.al and Patan, it included 36% and 10.7% respectively.^{21,22} Second commonest presentation in our study was found to be muscle pain or myalgia accounting for 20.2% whereas 1.85% of the total study population presented with myalgia in the study conducted by Balsam Qubais Saeed et.al.²³ 16.4% of the students presented with fatigue which holds to be the 3rd commonest presenting symptom which is higher in comparison to the study conducted by Osama Abu-Hammad et.al and Balsam Qubais Saeed et.al.^{21,23} Headache was found to be the commonest presentation accounting for 2.9% in first dose and 1.6% in the second dose which is deviant from our study as it accounts for 5.2% of the total study population being the fourth commonest presentation.²² In our study adverse effects were seen more in males as compared to females which are in contrast to the study conducted at Patan where effects of the vaccination were seen more in females than in males.²² 7.8% of the total population presented with Fever which is almost similar to the study conducted by Osama Abu-Hammad et.al (9%)²¹. In a developing country like Nepal with finite resources, the Vero cell has proven to be the most suitable one because of its easy accessibility, availability, and good efficacy.²⁴ Correlating our study with other studies, Pain at the injection site, Myalgia and Fatigue were found to be the top three commonest presentations whilst Pain at the injection site was commonest among all the studies. The least common symptoms included swelling, sneezing, sore throat, nausea, vomiting, dizziness, cough, and runny nose.22, 25-27

Conclusion:

The prevalence of side effects of the vaccine was found to be 75% after the first dose and 62% after the second dose. Pain at the injection site was the most common side effect after both doses. The severity of symptoms was more in males after the first dose, but in females after the second dose. There were no life-threatening side effects. A larger study on the general population including all age groups is highly recommended to detect all spectrum of side effects.

Acknowledgment:

We would like to acknowledge Dr. Prabesh Pant, Lecturer, Department of Internal Medicine, NGMC, Kohalpur, Banke for his invaluable support and guidance. We would like to acknowledge Dr. Shreedar Poudel, Intern Dr for his cooperation. We would also like to express our sincerest gratitude towards our participants for their time and co-operation.

Limitations:

Our study was conducted in a small center where the overall population was not included. All the spectra of side effects of the vaccine in a healthy group population were difficult to appreciate. Also, recall bias was significant.

Author Contributions

Conceptualization: Dr. Rupak K.C., Dr. Sibika Malla, Dr. Suraj Adhikari

Data Collection: Dr. Rupak K.C., Dr. Sibika Malla

Data Analysis: Mr. Aashish Jung Pandey

Methodology: Dr. Niranjan K.C.

Writing-original draft preparation: Dr. Rupak K.C., Dr. Sibika Malla, Mr. Saharoj Siddiqui

Review and editing: Dr. Suraj Adhikari, Dr. Rumi K.C.

Ethical approval: Dr. Rupak K.C., Dr. Sibika Malla, Dr. Merina Shrestha

Supervision: Dr. Merina Shrestha, Dr. Suraj Adhikari

Funding: No external funding was needed

REFERENCES:

1. World Health Organization. Naming corona virus disease and the virus that caused it [internet]. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019/technicalguidance/naming-t

2.Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, Zhao X, Huang B, Shi W, Lu R, Niu P, Zhan F, Ma X, Wang D, Xu W, Wu G, Gao GF, Tan W; China Novel Coronavirus Investigating and Research Team. A Novel Coronavirus from Patients with Pneumonia in China, 2019. N Engl J Med. 2020 Feb 20;382(8):727-733. DOI: 10.1056/NEJMoa2001017

3.World Health Organization (WHO). Archived: WHO Timeline - COVID-19. Available from: https://www.who.int/news/item/27-04-2020-who-timeline---covid-19; updated [2020 June 29]; cited [2021 June 27]

4.World Health Organization (WHO). The World Health Organization Just Declares COVID-19 a Pandemic. Available from: https://time.com/5791661/who-coronavirus-pandemic-declaration/; cited [2021 June 28]

5. Worldometer. COVID-19 coronavirus pandemic. Updated [2021 july 21]; cited [2021 july 21]. Available from: https://www.worldometers.info/coronavirus/

6.Zhu, Z., Lian, X., Su, X. et al. From SARS and MERS to COVID-19: a brief summary and comparison of severe acute respiratory infections caused by three highly pathogenic human coronaviruses. Respir Res 21, 224 (2020). DOI: https://doi.org/10.1186/s12931-020-01479-w

World Health Organization. Coronavirus Disease (COVID-2019) Situation Reports [Internet].26 7. Jan,2020. Available htpps://www.who.int/emergencies/diseases/novel-coronavirusfrom: 2019/situation-reports

8. David A.J. Coronavirus. 4th Edition. Tyrrell and Steven H. Myint. USA; National Library of Medicine. The University of Texas Medical Branch at Galveston;1996. NBK7782

9. Auwaerter P. Coronavirus: Johns Hopkins Abx Guide [Internet]. Coronavirus | Johns Hopkins ABX Guide. [cited 2021Jun28]. Available from: https://www.hopkinsguides.com/hopkins/view/Johns_Hopkins_ABX_Guide/540143/all/Coronavirus;

10. World Health Organization. Transmission of SARS-CoV-2: implications for infection prevention precautions [Internet]. Available from: https://www.who.int/newsroom/commentaries/detail/transmission-of-sars-cov-2-implications-for-infection-preventionprecautions ;updated [2020 July 9]; cited [2020 March 29]

11. Interim Clinical Guidance for Management of Patients with Confirmed Coronavirus Disease (COVID-19) [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; [cited 2022Jul22]. Available from: https://www.cdc.gov/coronavirus/2019ncov/hcp/clinical-guidance-management-patients.html#print

12. Bastola A, Sah R, Rodriguez-Morales AJ, Lal BK, Jha R, Ojha HC, et al. The first 2019 novel coronavirus case in Nepal. The Lancet Infectious Diseases. 2020;20(3):279-80.

13. Why are vaccinations needed? - THL [Internet]. Finnish Institute for Health and Welfare (THL). Finland. [cited 2022Jul23]. Available from: https://thl.fi/en/web/infectious-diseases-andvaccinations/information-about-vaccinations/why-are-vaccinations-needed-#:~:text=Vaccination%20is%20an%20effective%20and,of%20pathogens%20in%20the%20populatio n

medRxiv preprint doi: https://doi.org/10.1101/2022.12.22.2283763; this version posted December 22, 2022. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.

perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license .

14. Vaccines for covid-19 [Internet]. Centers for Disease Control and Prevention. Centers for Disease Control and Prevention; [cited 2021Jun28]. Available from: https://www.cdc.gov/coronavirus/2019-ncov/vaccines/index.html

15. Get the facts about covid-19 vaccines [Internet]. Mayo Clinic. Mayo Foundation for Medical Education and Research; 2022 [cited 2021Jun28]. Available from: https://www.mayoclinic.org/diseases-conditions/coronavirus/in-depth/coronavirus-vaccine/art-20484859

16. Vaccines candidates in clinical trials [Internet]. COVID. [cited 2022Feb2]. Available from: https://covid19.trackvaccines.org/vaccines/

17. Poudel A. Nepal begins first phase of Covid-19 vaccination drive. THE KATHMANDU POST [Internet]. 2021Jan27; Available from: https://tkpo.st/3poTrHD

18. All you need to know about Nepal's vaccination status [Internet]. THE KATHMANDU POST. 2021Jul21. Available from: https://tkpo.st/3B3qJCE

19. COVID-19 Vaccine (Vero cell), Inactivated. SINOVAC BIOTECH LTD.; 2021.

20. Pike H. Sinopharm COVID-19 vaccine: Should you worry about the side effects? -Martin YH, editor. MEDICALNEWSTODAY [Internet]. 2021May18; Available from: https://www.medicalnewstoday.com/articles/sinopharm-covid-19-vaccine-should-you-worry-about-the-side-effects

21.Abu-Hammad O, Alduraidi H, Abu-Hammad S, Alnazzawi A, Babkair H, Abu-Hammad A, et al. Side effects reported by Jordanian healthcare workers who received covid-19 vaccines. Vaccines. 2021;9(6):577.

22. Aryal S, Devbhandari RP, Shrestha S, Shrestha A, Rajbhandari P, Shakya T, et al. Adverse events following Sinopharm (Vero Cell), the inactivated COVID-19. Journal of Patan Academy of Health Sciences. 2021;8(2):18–24.

23. Saeed BQ, Al-Shahrabi R, Alhaj SS, Alkokhardi ZM, Adrees AO. Side effects and perceptions following Sinopharm covid-19 vaccination. International Journal of Infectious Diseases. 2021;111:219–26.

24.Who lists additional COVID-19 vaccine for emergency use and issues interim policy recommendations [Internet]. World Health Organization. World Health Organization; 2021 [cited 2022Apr6]. Available from: https://www.who.int/news/item/07-05-2021-who-lists-additional-covid-19-vaccine-for-emergency-use-and-issues-interim-policy-recommendations

25. Background document on the inactivated COVID-19 vaccine BIBP developed by China National Biotec Group (CNBG), Sinopharm, 7 May 2021 [Internet]. World Health Organization. World Health Organization; 2021 [cited 2022Jun16]. Available from:

 $https://www.who.int/publications/i/item/WHO-2019-nCoV-vaccines-SAGE_recommendation-BIBP-background-2021.1$

26. COVID-19 Vaccine Explainer. COVID-19 Vaccine (Vero Cell), Inactivated (Sinopharm). World Health Organization; 2021.

27. Who recommendation COVID-19 vaccine Beijing Institute of Biological Products Co., ltd.(bibp) /Sinopharm [Internet]. World Health Organization. World Health Organization;2022[cited2022Jul16]. Available from: https://extranet.who.int/pqweb/vaccines/who-recommendation-covid-19-vaccine-bibp